AMT three-lens brief
Evidence-based stock research on AMT. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 10% of its 52-week range — deep in the lower band.
- Trading at 10% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 9.8pp over 30 days.
- Analyst mean target $215.57 — 29% above current (23 analysts).
- Debt-to-equity of 445% — balance-sheet-heavy.
AMT closed at $167.60 (+1.58%) as of 2026-07-10. Market cap: $78.08B. P/E (trailing) 27.0. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $215.57 — 29% above current (23 analysts).. Concerns: trading at 10% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $2.74B, net income $859.50M, free cash flow $4.61B. Watching for: 2026-07-28 earnings release (17 days out).
Why three lenses on AMT, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AMTacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AMT" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AMT brief"></iframe>